Literature DB >> 33755703

Association of the systemic host immune response with acute hyperglycemia in mechanically ventilated septic patients.

Nauman Farooq1, Byron Chuan2, Hussain Mahmud3, Samar R El Khoudary4, Seyed Mehdi Nouraie2, John Evankovich2, Libing Yang5, Daniel Dunlap2, William Bain2,6, Georgios Kitsios2,7, Yingze Zhang2, Christopher P O'Donnell2, Bryan J McVerry2,7, Faraaz Ali Shah2,6.   

Abstract

Hyperglycemia during sepsis is associated with increased organ dysfunction and higher mortality. The role of the host immune response in development of hyperglycemia during sepsis remains unclear. We performed a retrospective analysis of critically ill adult septic patients requiring mechanical ventilation (n = 153) to study the relationship between hyperglycemia and ten markers of the host injury and immune response measured on the first day of ICU admission (baseline). We determined associations between each biomarker and: (1) glucose, insulin, and c-peptide levels at the time of biomarker collection by Pearson correlation; (2) average glucose and glycemic variability in the first two days of ICU admission by linear regression; and (3) occurrence of hyperglycemia (blood glucose>180mg/dL) by logistic regression. Results were adjusted for age, pre-existing diabetes mellitus, severity of illness, and total insulin and glucocorticoid dose. Baseline plasma levels of ST2 and procalcitonin were positively correlated with average blood glucose and glycemic variability in the first two days of ICU admission in unadjusted and adjusted analyses. Additionally, higher baseline ST2, IL-1ra, procalcitonin, and pentraxin-3 levels were associated with increased risk of hyperglycemia. Our results suggest associations between the host immune response and hyperglycemia in critically ill septic patients particularly implicating the interleukin-1 axis (IL-1ra), the interleukin-33 axis (ST2), and the host response to bacterial infections (procalcitonin, pentraxin-3).

Entities:  

Year:  2021        PMID: 33755703      PMCID: PMC7987165          DOI: 10.1371/journal.pone.0248853

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  61 in total

1.  Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis.

Authors:  Yee Ting Lee; Mengqi Gong; Alex Chau; Wing Tak Wong; George Bazoukis; Sunny Hei Wong; Konstantinos Lampropoulos; Yunlong Xia; Guangping Li; Martin C S Wong; Tong Liu; William K K Wu; Gary Tse
Journal:  J Infect       Date:  2017-11-23       Impact factor: 6.072

2.  Early initiation of low-level parenteral dextrose induces an accelerated diabetic phenotype in septic C57BL/6J mice.

Authors:  Srikanth Singamsetty; Faraaz Ali Shah; Lanping Guo; Yoshio Watanabe; Sherie McDonald; Rohit Sharma; Yingze Zhang; Laura C Alonso; Christopher P O'Donnell; Bryan J McVerry
Journal:  Appl Physiol Nutr Metab       Date:  2015-09-09       Impact factor: 2.665

3.  Association of serum pentraxin 3 concentrations with diabetic nephropathy.

Authors:  Rui Wang; Jietao Zhang; Wenchao Hu
Journal:  J Investig Med       Date:  2016-05-27       Impact factor: 2.895

Review 4.  Stress-induced hyperglycemia.

Authors:  K C McCowen; A Malhotra; B R Bistrian
Journal:  Crit Care Clin       Date:  2001-01       Impact factor: 3.598

5.  Interleukin-33 prevents the development of autoimmune diabetes in NOD mice.

Authors:  Jingli Lu; Yan Liang; Junjie Zhao; Haiyang Meng; Xiaojian Zhang
Journal:  Int Immunopharmacol       Date:  2019-02-16       Impact factor: 4.932

6.  Glycemic variability: a strong independent predictor of mortality in critically ill patients.

Authors:  James S Krinsley
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

7.  Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations.

Authors:  Wen-Kui Yu; Wei-Qin Li; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

9.  Soluble ST2 has a prognostic role in patients with suspected sepsis.

Authors:  Mina Hur; Hanah Kim; Hyun Jeong Kim; Hyun Suk Yang; Laura Magrini; Rossella Marino; Patrizia Cardelli; Salvatore Di Somma
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

Review 10.  Procalcitonin--a new indicator of the systemic response to severe infections.

Authors:  W Karzai; M Oberhoffer; A Meier-Hellmann; K Reinhart
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.